SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 – A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts
Open forum infectious diseases
; 2022.
Article
in English
| EuropePMC | ID: covidwho-1823878
ABSTRACT
The potential preventive efficacy of tenofovir/emtricitabine on SARS-CoV-2 infection was assessed in HIV pre-exposition prophylaxis (PrEP) users. Prevalence of SARS-CoV-2 IgG between May and October 2020 was similar in PrEP users and in a matched population-based cohort suggesting that tenofovir/emtricitabine has no role in reducing the risk of SARS-CoV-2 acquisition.
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Language:
English
Journal:
Open forum infectious diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS